Sort by
Refine Your Search
-
malignancies. Leukemia. 2023;37(4):864-876. Kumar S, Schoonderwoerd MJA, Kroonen JS, et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell
-
Context: Fault injection allows an attacker to move the target processor out of its expected functioning bounds. A hardware perturbation, by means of a fault injection, aims at inducing logical
-
multinational environment and interact positively with team members and stakeholders Flexibility, adaptability, autonomy, target and detail-oriented Rigor, motivation, conciseness, sense of priority Past
-
of the MICRO-PATH doctoral training unit is to tackle these challenges in a focused way and to lay the foundation for establishing the microbiome as a therapeutic and preventative target in the future
-
name of the targeted Institutes should appear on the main front page. C3M: sophie.tartare-deckert@univ-cotedazur.fr iBV: ibv.direction@univ-cotedazur.fr IPMC : lesage@ipmc.cnrs.fr IRCAN : Dmitry.BULAVIN
-
the targeted Institutes should appear on the main front page. C3M: sophie.tartare-deckert@univ-cotedazur.fr iBV: ibv.direction@univ-cotedazur.fr IPMC : lesage@ipmc.cnrs.fr IRCAN : Dmitry.BULAVIN@univ
-
list below). The reference of the chair (Chemistry of Biological Systems) and the name of the targeted Institutes should appear on the main front page. C3M: sophie.tartare-deckert@univ-cotedazur.fr iBV
-
mass spectrometry and cheminformatics software and workflows, primarily for target and non-target metabolomics, exposomics and environmental analysis within the Environmental Cheminformatics Group and
-
Postdoctoral position: Developing a human lymphoid organ-on-chip to evaluate candidate mRNA vaccines
on the LO chip, to better evaluate the potential of candidate mRNA vaccines to target mucosal pathogens. Further developments will aim at evaluating the predictive power of the LO chip assay and at increasing
-
Programmed Cell Death-1 (PD-1). PD-1 targeted therapies elicit clinical responses in different cancertypes, but response rates are rarely above 20%. Positive outcomes have been associated with CD8T cell